Monocyte or white blood cell counts and β 2 microglobulin predict the durable efficacy of daratumumab with lenalidomide.
Yutaka ShimazuJunya KandaHitomi KanekoKazunori ImadaRyosuke YamamuraSatoru KosugiYuji ShimuraTomoki ItoShin-Ichi FuchidaHitoji UchiyamaKentaro FukushimaSatoshi YoshiharaHitoshi HanamotoHirokazu TanakaNobuhiko UoshimaKensuke OhtaHideo YagiHirohiko ShibayamaYoshiyuki OndaYasuhiro TanakaYoko AdachiMitsuhiro MatsudaMasato IidaTakashi MiyoshiToshimitsu MatsuiRyoichi TakahashiTeruhito TakakuwaMasayuki HinoNaoki HosenShosaku NomuraChihiro ShimazakiItaru MatsumuraAkifumi Takaori-KondoJunya Kurodanull nullPublished in: Therapeutic advances in hematology (2022)
< 0.001). To confirm this concept, our results will need to be validated in other cohorts.